The Price of Innovation: How Government Controls Could Stifle Breakthroughs in Medicine The recent proposal from the Centers for Medicare & Medicaid Services (CMS) to broaden the criteria for grouping medicines together under price controls has sent shockwaves through the pharmaceutical industry.
At first glance, this move might seem like a harmless tweak to an existing policy. However, it has far reaching implications that could stifle innovation in medicine.
One of the most significant consequences of this proposal is its potential to discourage investment in new medicines.